Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy

CONTEXT: Cephaeline is a natural product isolated from ipecac (Cephaelis ipecacuanha [Brot.] A. Rich. [Rubiaceae]). It exhibits promising anti-lung cancer activity and ferroptosis induction may be a key mechanism for its anti-lung cancer effect.

OBJECTIVES: This study investigates the anti-lung cancer activity and mechanisms of cephaeline both in vitro and in vivo.

MATERIALS AND METHODS: H460 and A549 lung cancer cells were used. The cephaeline inhibition rate on lung cancer cells was detected via a Cell Counting Kit-8 assay after treatment with cephaeline for 24 h. Subsequently, the concentrations of 25, 50 and 100 nM were used for in vitro experiments. In addition, the antitumour effects of cephaeline (5, 10 mg/kg) in vivo were evaluated after 12 d of cephaeline treatment.

RESULTS: Cephaeline showed significant inhibitory effects on lung cancer cells, and the IC50 of cephaeline on H460 and A549 at 24, 48 and 72 h were 88, 58 and 35 nM, respectively, for H460 cells and 89, 65 and 43 nM, respectively, for A549 cells. Meanwhile, we demonstrated that ferroptosis is the key mechanism of cephaeline against lung cancer. Finally, we found that cephaeline induced ferroptosis in lung cancer cells by targeting NRF2.

DISCUSSION AND CONCLUSION: We demonstrated for the first time that cephaeline inhibits NRF2, leading to ferroptosis in lung cancer cells. These findings may contribute to the development of innovative therapeutics for lung cancer.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:62

Enthalten in:

Pharmaceutical biology - 62(2024), 1 vom: 05. Feb., Seite 195-206

Sprache:

Englisch

Beteiligte Personen:

Chen, Peng [VerfasserIn]
Ye, Qingxuan [VerfasserIn]
Liang, Shang [VerfasserIn]
Zeng, Linghui [VerfasserIn]

Links:

Volltext

Themen:

Cephaelin
Emetine
GPX4
Ipecac
Journal Article
NF-E2-Related Factor 2
Natural products
QA971541A1
SLC7A11
TBHQ
X8D5EPO80M

Anmerkungen:

Date Completed 14.02.2024

Date Revised 15.02.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/13880209.2024.2309891

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368293017